5-Amino-1MQ vs Tesofensine
Research Verdict
Tesofensine is the stronger research reference for the stated comparison criteria. Tesofensine: Phase 2b RCT (Astrup et al.
Quick Answers
Which is better, 5-Amino-1MQ or Tesofensine?
Tesofensine is the stronger research reference for the stated comparison criteria. Tesofensine: Phase 2b RCT (Astrup et al.
What is the key difference between 5-Amino-1MQ and Tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) with central appetite suppression; 5-Amino-1MQ is a peripheral NNMT inhibitor targeting cellular metabolism - CNS vs. peripheral mechanisms with very different safety profiles.
Evidence Comparison
Tesofensine: Phase 2b RCT (Astrup et al. Lancet 2008, n=203) showing 10.6% weight loss at 0.5 mg dose over 24 weeks - strong human efficacy signal. 5-Amino-1MQ: zero human data, single research group. Tesofensine is vastly stronger on evidence.
Evidence Context Favoring 5-Amino-1MQ
Preclinical NNMT or NAD+ metabolism research not requiring human data.
Evidence Context Favoring Tesofensine
Weight loss research requiring human efficacy evidence, accepting the CNS side-effect profile inherent to triple reuptake inhibitors.
Side-by-Side Snapshot
| Evidence grade | 5-Amino-1MQ: Level D Tesofensine: Level B |
|---|---|
| Research status | 5-Amino-1MQ: Preclinical Tesofensine: Phase 3 |
| Primary category | 5-Amino-1MQ: Weight Loss & Metabolic Tesofensine: Weight Loss & Metabolic |
| Cited studies | 5-Amino-1MQ: 2 Tesofensine: 2 |